NCT00423683View on ClinicalTrials.gov

Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism

PHASE3TerminatedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
CancerThromboembolism
Interventions
DRUG

Arixtra alone

Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)

DEVICE

Arixtra + filter

Arixtra as daily injections similar to arm I and placement of Inferior Vena Cava (IVC) filter.

Trial Locations (1)

11030

North Shore University Hospital, Manhasset

Sponsors

Lead Sponsor

Northwell Health

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Northwell Health

OTHER

NCT00423683 - Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism | Biotech Hunter | Biotech Hunter